Cedric Hermans/ institutroialbertdeux.be;
Jan Blatný/praguemorning.cz
Apr 1, 2026, 11:46
Cedric Hermans: Revisiting the Role of Factor VIII in Haemophilia A in 2026 on E-Learning Insights
Cedric Hermans, Head of Haemophilia Centre at the Saint-Luc University Hospital, Brussels, shared a post on LinkedIn:
“Revisiting the role of FVIII in Haemophilia A in 2026
In this episode, Cedric Hermans sits down with Jan Blatný, Consultant Haematologist at Masaryk University and University Hospital Brno, EHCC and EuroBloodNet Centre, and former EAHAD President (2024–2026), to explore the evolving role of Factor VIII in the management of haemophilia A in 2026.
As new therapies such as emicizumab, rebalancing agents, and gene therapy reshape the treatment landscape, this conversation revisits where FVIII remains essential.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 13:03Amira Mohy: Diagnostic Flow Cytometry Panels for Hematological Malignancies
-
Sep 30, 2026, 12:52Paul Watton: Could Repetitive Head Impacts Leave a Molecular Memory?
-
Sep 30, 2026, 12:41The Journey to ISTH 2027 Starts in Vancouver
-
Sep 30, 2026, 11:36Basit Ali: A Closer Look at CT Venography
-
Sep 30, 2026, 11:16Christina Pohlman: Could aPL Levels Help Predict Stroke Recurrence?
-
Sep 30, 2026, 10:55Rana Al Hrout: Diagnostic Approach to Hypochromic Microcytic Anemia
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate